Prognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis - Summary - MDSpire
Advertisement
Prognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis
To investigate the association of surgical resection at 1st recurrence with progression-free survival after recurrence (PFS-2) and survival after recurrence (SAR) in IDH-mutant lower-grade glioma patients, highlighting the clinical significance of these outcomes.
Key Findings:
148 patients analyzed, with a balanced distribution of WHO grade 2 (49.3%) and grade 3 (50%) tumors, and statistical significance noted for GTR outcomes.
33.8% of patients underwent repeat resection at 1st recurrence, with implications for treatment decisions.
Gross total resection (GTR) was associated with improved PFS-2 and SAR compared to non-surgical treatment, emphasizing the need for surgical intervention.
Interpretation:
Surgical resection at initial recurrence, particularly GTR, may confer a survival benefit in IDH-mutant lower-grade glioma patients, highlighting the importance of tailored treatment strategies and the need for clinical guidelines.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the validity of the findings.
Limited generalizability due to single-institution study, suggesting caution in applying results broadly.
Potential confounding factors not fully accounted for in analysis, which may influence outcomes.
Conclusion:
Repeat surgical resection at 1st recurrence in IDH-mutant lower-grade gliomas is associated with favorable outcomes, suggesting a need for further studies to standardize treatment approaches and explore the long-term effects of surgical intervention.
Baptist Health Miami Neuroscience Institute invites Dr. Roy A. Bakay to discuss emerging developments in functional neurosurgery and restorative therapies for neurological disorders.
